3 Trending Vaccine Stocks To Check Out Right Now
Like it or not, it has been a banner year for coronavirus vaccine stocks in the stock market. After all, seeing as we are still fighting off a global pandemic, this would make sense. Even now, as parts of the world are still working to vaccinate their populations, the top names in the field remain hard at work. If anything, there are also plenty of emerging companies in this field as well. With more variants of concern to consider among other factors, second-generation vaccine companies would have a knowledge advantage over frontrunners.
Whether you are a believer in upcoming names or established companies, investors are spoilt for choices now. On one hand, companies such as Ocugen (NASDAQ: OCGN) or Vaxart (NASDAQ: VXRT) are still developing their vaccines. On the other hand, there are also numerous companies that are now seeking approval for their coronavirus vaccines. This could appeal to investors looking to jump on the early adopter train with the rising vaccine star.
Not to mention, top players Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) continue to break new ground. Earlier today, the duo revealed data showing the effectiveness of their vaccine in children. Particularly, data suggests that their vaccine candidate induced a robust immune response in 5 to 11-year-olds. As a result, the duo is planning to apply for authorization for use in children in the U.S. and Europe among other regions. With all that said, here are three notable vaccine stocks to watch in the stock market today.
Best Vaccine Stocks To Watch Today
Starting us off today is Novavax. Now, this upcoming name in the vaccine space has and continues to make headlines globally. This would be the case as demand for the company’s coronavirus vaccine is already building despite Novavax not receiving FDA approval yet. In brief, Novavax is a biotech company that primarily focuses on developing vaccines for infectious diseases. Aside from its COVID-19 vaccine, the company is also working on vaccines for Ebola, influenza, and respiratory syncytial virus to name a few.
Notably, NVAX stock is already looking at gains of over 95% year-to-date. Thanks to its latest vaccine manufacturing update, I could see these gains continue. In detail, Novavax now expects to produce at least 2 billion doses of its coronavirus vaccine in 2022. This would be in line with the company’s plans to apply for emergency use of its vaccine in the fourth quarter of 2021. With Novavax’s vaccine candidate showing the efficacy of over 90% in late-stage U.S.-based trials, NVAX stock could be in focus now.
Furthermore, CCO John Trizzino provided an informative update on the company’s long-term production plans as well. According to Trizzino, Novavax is now “engaging in conversations about incremental procurement for the second half of 2022, as well as early 2023.” All in all, should the pandemic turn to an endemic as suggested by top epidemiologists, Novavax’s vaccines would remain viable. As such, would you consider NVAX stock a top buy now?
Following that, we will be taking a look at the vaccine company, AstraZeneca. In brief, the British-Swedish multinational pharmaceutical firm is a major presence in the global biotech industry today. Through its operations, AstraZeneca discovers, develops, and commercializes a wide array of prescription medicines. The likes of which cover medical fields such as Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, and Immunology among others. For a sense of scale, the company operates in over 100 countries while its treatments are used by millions of patients worldwide.
After considering all of this, would it be wise to keep an eye on AZN stock? Sure, more investors could be eyeing the company’s shares now given its coronavirus vaccine. However, AstraZeneca does not seem to be resting on its laurels when it comes to its other work in the biotech world now. Over the weekend, the company reported two upbeat developments within its oncology portfolio.
To begin with, clinical trials of AstraZeneca’s metastatic breast cancer (MBC) treatment, Enhertu, yielded significantly positive results. According to the company, Enhertu reduced the risk of disease progression or death by 72% in comparison with conventional treatments in patients with HER2-positive MBC. At the same time, AstraZeneca’s Imfinzi, a small cell lung cancer treatment also produced notable results. When used together with chemotherapy, the company found that Imfinzi tripled patient survival to up to three years. Given AstraZeneca’s current momentum, will you be adding AZN stock to your portfolio this week?
Johnson & Johnson
Next, we have Johnson & Johnson or more commonly referred to as JNJ. By JNJ’s estimates, it is currently the world’s largest and most broadly-based health care company. This would be the case seeing as the company is a leading developer and provider of health care goods and services. Notably, JNJ would be another name to note among coronavirus vaccine stocks given its single-dose regimen candidate. Moreover, investors could be eyeing the company’s shares now as dividend stocks gain traction amidst the current stock market volatility.
While all that builds the case for JNJ stock, the company continues to press forward on the operational front. Just last week, JNJ revealed solid data on its Ebola vaccine regimen, Zabdeno. According to JNJ, Zabdeno generated robust humoral (antibody) immune responses in both adults and children aged 1 to 17. Additionally, immune responses persisted for at least two years in adults within the study. CEO Paul Stoffels believes that this peer-reviewed data supports the use of Zabdeno to protect people at risk of contracting Ebola.
Overall, JNJ’s operations span far and wide, even beyond its coronavirus vaccine work. Evidently, the company remains hard at work solving various other illnesses worldwide. As a global health care innovator and provider, it could be a viable bet for investors looking to play on the defensive now. With all this in mind, will you be keeping an eye on JNJ stock right now?